Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vesuvius not expecting any improvement in performance until 2026

(Sharecast News) - Molten metal flow engineering company Vesuvius slumped on Thursday as it said market conditions remained challenging and that it does not expect an improvement in its performance until 2026. In an update on the first half, Vesuvius said it had seen a continuation of the challenging market conditions highlighted in the trading update in May, with the wider uncertain macroeconomic environment and subdued global industrial activity persisting. This has led to continuing weakness in its end markets.

As a result, trading profit in the first half of 2025 is expected to be about £77m, consistent with the company's expectations and reflecting both short-term cost reduction actions and "the strong progress" of its structural cost reduction programme.

"Contrary to our previous expectations, we now anticipate that these challenging market conditions will persist for the balance of the year," it said.

"Consequently, the pricing environment remains difficult, in particular in Europe and China, limiting for the time being our ability to fully recover labour cost inflation. We however anticipate progressively improving our pricing performance over the second half of the year to partially recover those costs, albeit with a delayed effect."

As a result, the group now expect its second-half performance to be similar to the first, with further progress postponed until 2026.

At 1035 BST, the shares were down 6% at 364p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.